These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 23921309)

  • 1. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.
    Shi J; Wei L
    J Cardiovasc Pharmacol; 2013 Oct; 62(4):341-54. PubMed ID: 23921309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rho kinase as a therapeutic target in cardiovascular disease.
    Surma M; Wei L; Shi J
    Future Cardiol; 2011 Sep; 7(5):657-71. PubMed ID: 21929346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling through Rho GTPase pathway as viable drug target.
    Lu Q; Longo FM; Zhou H; Massa SM; Chen YH
    Curr Med Chem; 2009; 16(11):1355-65. PubMed ID: 19355891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small guanine nucleotide-binding protein Rho and myocardial function.
    Ren J; Fang CX
    Acta Pharmacol Sin; 2005 Mar; 26(3):279-85. PubMed ID: 15715922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
    Shimokawa H; Satoh K
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
    Raja SG
    Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):100-4. PubMed ID: 22670803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho-kinase: important new therapeutic target in cardiovascular diseases.
    Satoh K; Fukumoto Y; Shimokawa H
    Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H287-96. PubMed ID: 21622831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
    Zhou H; Li YJ
    Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells.
    Ohta T; Takahashi T; Shibuya T; Amita M; Henmi N; Takahashi K; Kurachi H
    Cancer Biol Ther; 2012 Jan; 13(1):25-33. PubMed ID: 22336585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Insights into the Roles of Rho Kinase in Cancer.
    Wei L; Surma M; Shi S; Lambert-Cheatham N; Shi J
    Arch Immunol Ther Exp (Warsz); 2016 Aug; 64(4):259-78. PubMed ID: 26725045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm.
    Dong M; Yan BP; Yu CM
    Cardiovasc Hematol Agents Med Chem; 2009 Oct; 7(4):322-30. PubMed ID: 19607644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RhoA/ROCK Pathway Ameliorates Adhesion and Inflammatory Infiltration Induced by AGEs in Glomerular Endothelial Cells.
    Rao J; Ye Z; Tang H; Wang C; Peng H; Lai W; Li Y; Huang W; Lou T
    Sci Rep; 2017 Jan; 7():39727. PubMed ID: 28054559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ethanol on RhoA/Rho-kinase-mediated calcium sensitization in mouse lung parenchymal tissue.
    Aydinoglu F; Ergurhan Kiroglu O; Astarci E; Balli E; Ogulener N
    Eur J Pharmacol; 2015 Oct; 764():318-327. PubMed ID: 26169563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of RhoA/ROCK signaling pathway ameliorates hypoxic pulmonary hypertension via HIF-1α-dependent functional TRPC channels.
    Wang XY; Mo D; Tian W; Liu XX; Zhou YG; Sun Y; Feng YD; Xiao X; Hao XW; Zhang HN; Li C; Cao W; Li XQ
    Toxicol Appl Pharmacol; 2019 Apr; 369():60-72. PubMed ID: 30831131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
    Chen XY; Dun JN; Miao QF; Zhang YJ
    Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling.
    Lai D; Gao J; Bi X; He H; Shi X; Weng S; Chen Y; Yang Y; Ye Y; Fu G
    J Mol Med (Berl); 2017 Feb; 95(2):155-165. PubMed ID: 27576917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress of the study of rho-kinase and future perspective of the inhibitor.
    Tawara S; Shimokawa H
    Yakugaku Zasshi; 2007 Mar; 127(3):501-14. PubMed ID: 17329936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RhoA/Rho-Kinase in the Cardiovascular System.
    Shimokawa H; Sunamura S; Satoh K
    Circ Res; 2016 Jan; 118(2):352-66. PubMed ID: 26838319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.
    Al-Hilal TA; Hossain MA; Alobaida A; Alam F; Keshavarz A; Nozik-Grayck E; Stenmark KR; German NA; Ahsan F
    J Control Release; 2021 Jun; 334():237-247. PubMed ID: 33915222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
    Xu EZ; Kantores C; Ivanovska J; Engelberts D; Kavanagh BP; McNamara PJ; Jankov RP
    Am J Physiol Heart Circ Physiol; 2010 Dec; 299(6):H1854-64. PubMed ID: 20889845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.